Clinical Trial Update: ONO-5920/YM529 Confirmatory Study in Involutional Osteoporosis Patients [Phase 2, Phase 3]

View source ↗

Summary

The confirmatory study of ONO-5920/YM529 in involutional osteoporosis (Phase 2/Phase 3) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis

Drugs mentioned

• YM529/ONO-5920 (YM529)

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Osteoporosis, Bone Loss, Age-Related | Phase 2, Phase 3 | Status: COMPLETED